Popular Diabetes Medication linked to Pancreatic Cancer
Byetta, Januvia, Victoza are several popular Type 2 diabetes drugs that over the years, have been linked to pancreatic cancer.
In 2007 The Food and Drug Administration began issuing alerts regarding concerns of increased risk of acute pancreatitis in patients who have taken Byetta, a drug manufactured by Amylin Pharmaceuticals.
In 2009, the FDA received over 80 complaints from patients who were diagnosed with pancreatitis after using Januvia, leading the FDA to publicly warn that Januvia could cause pancreatitis, which could manifest into pancreatic cancer.
In 2011, the University of California preformed a study that reviewed data compiled by the FDA regarding unfavorable events involving patients who used these Type 2 diabetes drugs. The study concluded that patients who used Byetta or Januvia had 3 times the risk of pancreatic cancer.
On March 14, 2013, the FDA issued a Drug Safety Communication with regard to Victoza and other type 2 diabetes medications. The study concluded that use of the drugs was linked to an increased risk of pancreatitis and pre-cancerous cellular changes, also referred to as pancreatic duct metaplasia. These risks were prevalent in a certain type of medication, namely, incretin mimetics. The following are some of the more popular brand names of this type – Byetta, Bydureon, Victoza, Januvia and other.
Products and Manufacturers
Diabetes medications make up approximately $40 billion in annual sales in the pharmaceutical market to date, and most of them are safe and have not been recalled by the FDA. Yet, since some studies do show links between diabetes drugs and pancreatitis or pancreatic cancer and law firms are pursing active claims.
Most claims involve the following side effects:
- Pancreatic Cancer
- Thyroid Cancer
Listed below are some of the products and manufactures involved in claims:
- Byetta, Amylin and Ely Lilly Pharmaceuticals
- Januvia, Merck & Company
- Victoza, Novo Nordisk
- Onglyza, Bristol Myers Squibb
- Kombiglyze, Bristol Myers Squibb
- Nesina, Takeda Pharmaceuticals
- Kazano, Takeda Pharmaceuticals
- Tradjenta, Boehringer Ingelheim
- Jentaduento, Boehringer Ingelheim